Competition in the Irish Private Health Insurance Market

More documents

Recommendations

Info

6. BARRIERS TO RIVALRY ___________________________________________________ 87 SUMMARY ____________________________________________________________________ 87 SWITCHING COSTS ______________________________________________________________ 87 EVIDENCE ON SWITCHING ________________________________________________________ 89 PRICE SENSITIVITY______________________________________________________________ 91 SWITCHING - RENEWAL NOTICES___________________________________________________ 91 WAITING PERIODS ______________________________________________________________ 92 PROVISION OF INFORMATION ______________________________________________________ 93 SEARCH COSTS_________________________________________________________________ 94 SWITCHING PROCESS ____________________________________________________________ 96 TRAVEL INSURANCE_____________________________________________________________ 98 MINIMUM BENEFIT REGULATIONS __________________________________________________ 99 IMPACT OF COMMENCEMENT OF RE PAYMENTS ON EXISTING INSURERS ___________________ 100 REGULAR REVIEW OF RE SCHEME_________________________________________________ 101 7. BUYER POWER IN THE PHI MARKET______________________________________ 103 SUMMARY ___________________________________________________________________ 103 WHAT IS BUYER POWER?________________________________________________________ 103 BUYER POWER AND CONCENTRATED MARKETS ______________________________________ 104 THE IMPACT OF BUYER POWER ON CONSUMERS ______________________________________ 104 BUYER POWER AND ECONOMIC WELFARE___________________________________________ 105 MARKET STRUCTURE AND BUYER POWER___________________________________________ 105 THE SUPPLY OF PRIVATE MEDICAL FACILITIES _______________________________________ 106 PROVIDER NEGOTIATIONS _______________________________________________________ 107 IS BUYER POWER IN THE IRISH PHI MARKET PROBLEMATIC? _____________________________ 108 COUNTERVAILING EFFICIENCIES __________________________________________________ 108 THE SUPPLY OF HOSPITAL CONSULTANT SERVICES____________________________________ 111 SUPPLIER-INDUCED DEMAND_____________________________________________________ 112 AN ANALYTICAL FRAMEWORK FOR BUYER POWER____________________________________ 113 IMPACT OF NEW HOSPITALS – PREFERRED PROVIDER NETWORKS ________________________ 115 CONCLUSION _________________________________________________________________ 116 8. CONCENTRATION AND MARKET POWER IN THE PHI MARKET ____________ 118 SUMMARY ___________________________________________________________________ 118 WHAT IS MARKET POWER? ______________________________________________________ 118 EFFECTS OF MARKET POWER ON RIVALRY AND ENTRY_________________________________ 121 WHAT IS DOMINANCE?__________________________________________________________ 121 RECENT DEVELOPMENTS IN THE HEALTH INSURANCE MARKET __________________________ 121 MARKET CONCENTRATION_______________________________________________________ 122 COMPETITION FROM EXISTING COMPETITORS ________________________________________ 123 CONSUMER BUYER POWER ______________________________________________________ 125 THREAT OF COMPETITION FROM POTENTIAL NEW ENTRANTS ____________________________ 126 EXPANSION BY COMPETITORS ____________________________________________________ 127 THE FINANCIAL PERFORMANCE OF VHI HEALTHCARE__________________________________ 129 THE EFFECT OF RECENT DEVELOPMENTS ___________________________________________ 131 CONCLUSION _________________________________________________________________ 131 9. STRUCTURE OF THE HEALTH INSURANCE MARKET _________________________ 133 SUMMARY ___________________________________________________________________ 133 A STRUCTURAL APPROACH TO VHI HEALTHCARE_____________________________________ 133 APPENDIX 1 __________________________________________________________________ 138 OTHER FORMS OF HEALTH RELATED INSURANCE ______________________________________ 138 APPENDIX 2 __________________________________________________________________ 140 REPORT OF UK GOVERNMENT ACTUARY’S DEPARTMENT COMPARING THE IRISH AND AUSTRALIAN RE SYSTEMS _________________________________________________________________ 140 APPENDIX 3 __________________________________________________________________ 150 3
CONSUMER ATTITUDES TO SWITCHING _____________________________________________ 150 APPENDIX 4 __________________________________________________________________ 153 HOSPITAL WAITING TIMES IN THE PRIVATE AND PUBLIC SYSTEMS ________________________ 153 APPENDIX 5 __________________________________________________________________ 154 OECD REVIEW OF PHI _________________________________________________________ 154 APPENDIX 6 __________________________________________________________________ 160 LIST OF SUBMISSIONS___________________________________________________________ 160 APPENDIX 7 __________________________________________________________________ 161 UNDERSTANDING AND COMPARING HEALTH INSURANCE PRODUCTS. ______________________ 161 BIBLIOGRAPHY ______________________________________________________________ 165 4
Page 1 and 2: A Report to the Minister for Health
Page 3: CONTENTS TABLE OF FIGURES _________
Page 7 and 8: EXECUTIVE SUMMARY AND RECOMMENDATIO
Page 9 and 10: As a result it does not have to sat
Page 11 and 12: Recommendation 7 The Minister for H
Page 13 and 14: indicates that consumers of PHI hav
Page 15 and 16: Recommendation 13 The Minister for
Page 17 and 18: is quite unclear, so far as the Aut
Page 19 and 20: 1.4 For the next number of months t
Page 21 and 22: other insurers were to enter the ma
Page 23 and 24: 2.6 Private health insurance (PHI)
Page 25 and 26: 2.17 Open enrolment and lifetime co
Page 27 and 28: • 2001: The Health Insurance Auth
Page 29 and 30: Figure 2: Annual Change in PHI memb
Page 31 and 32: of medical inflation and the higher
Page 33 and 34: VIVAS Health is rising steadily. In
Page 35 and 36: • Table 1 below shows the annual
Page 37 and 38: Figure 6: PHI Products BUPA Ireland
Page 39 and 40: • Work-based group schemes where
Page 41 and 42: from year to year and also during t
Page 43 and 44: 3. DEFINING THE PRIVATE HEALTH INSU
Page 45 and 46: Figure 7: Key features of Related H
Page 47 and 48: price increase unprofitable by a hy
Page 49 and 50: 4.6 Aspects of the exemption from i
Page 51 and 52: and quarterly management accounts t
Page 53 and 54: Table 4: Regulation of PHI Firms 48
Page 55 and 56:
4.31 This is a positive step. Just
Page 57 and 58:
obliges Vhi Healthcare to seek appr
Page 59 and 60:
4.41 In the regulatory approval pro
Page 61 and 62:
4.50 However, the Authority is clea
Page 63 and 64:
Unfunded Lifetime Community Rating
Page 65 and 66:
President of the Society of Actuari
Page 67 and 68:
− The main other deterrent at pre
Page 69 and 70:
o The former members of the Advisor
Page 71 and 72:
materially affected by any seasonal
Page 73 and 74:
It may also be noted that the propo
Page 75 and 76:
4.94 There are 37 health insurers i
Page 77 and 78:
Interviews with Possible New Entran
Page 79 and 80:
have shown that new sales and switc
Page 81 and 82:
not binding on incumbents and no in
Page 83 and 84:
5.33 In this context Vhi Healthcare
Page 85 and 86:
5.44 As the former incumbent monopo
Page 87 and 88:
5.52 Vhi Healthcare’s first mover
Page 89 and 90:
• Psychological costs 6.5 Transac
Page 91 and 92:
18-24 9% 13% 25-34 34% 19% 35-44 31
Page 93 and 94:
6.24 The provision of renewal notic
Page 95 and 96:
The HIA publishes on its website a
Page 97 and 98:
Recommendation 10 Following consult
Page 99 and 100:
Recommendation 11 The insurance com
Page 101 and 102:
Regulations were established to aff
Page 103 and 104:
transferred and the amounts require
Page 105 and 106:
Buyer Power and Concentrated Market
Page 107 and 108:
The Supply of Private Medical Facil
Page 109 and 110:
VIVAS Health claims that Vhi Health
Page 111 and 112:
approval on coverage of facilities
Page 113 and 114:
Supplier-Induced Demand 7.36 The Vh
Page 115 and 116:
Questions Relevant evidence Irish P
Page 117 and 118:
to restrict individual choice of pr
Page 119 and 120:
8. CONCENTRATION AND MARKET POWER I
Page 121 and 122:
gives us some indication of the com
Page 123 and 124:
wishes to retain the flexibility to
Page 125 and 126:
largest price increase that is prof
Page 127 and 128:
scheme. Employees may be under the
Page 129 and 130:
elevant regulatory requirements, ex
Page 131 and 132:
Table 7 Vhi Healthcare Financial Re
Page 133 and 134:
• There is limited buyer power fr
Page 135 and 136:
Breaking up Vhi Healthcare would di
Page 137 and 138:
expertise and other staff resources
Page 139 and 140:
APPENDIX 1 Other forms of health re
Page 141 and 142:
APPENDIX 2 Report of UK Government
Page 143 and 144:
Australia Ireland Public hospital U
Page 145 and 146:
Australia Ireland Risk equalisation
Page 147 and 148:
1.22 The Irish data is not split at
Page 149 and 150:
Conclusion of normal claim payments
Page 151 and 152:
APPENDIX 3 Consumer Attitudes to Sw
Page 153 and 154:
Survey Respondent factors promoting
Page 155 and 156:
APPENDIX 5 OECD Review of PHI The O
Page 157 and 158:
not-for-profit insurers has posed c
Page 159 and 160:
114. Private insurers have not impl
Page 161 and 162:
APPENDIX 6 List of Submissions The
Page 163 and 164:
Understanding and Comparing Private
Page 165 and 166:
Benefits Outpatient Cover Cover for
Page 167 and 168:
Dobson, P., M. Waterson and A. Chu,
Page 169:
Vhi Healthcare (2005), Annual Repor
show all

Competition in the Irish Private Health Insurance Market

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?